HB 1178 would create a comprehensive medical marijuana program in Indiana, effective July 1, 2025. The bill authorizes patients with a “serious medical condition,” as determined by a physician, to use medical marijuana and establishes a regulatory framework for cultivation, processing, testing, transportation, dispensing, and research. The Indiana Department of Health would administer the program, issue permits and patient/caregiver identification cards, maintain a tracking database, conduct inspections, adopt rules, and enforce compliance. The bill also sets up an oversight committee to review appeals and grievances related to the program.
The measure includes detailed rules for physician certifications, patient eligibility, caregiver designation, home cultivation, dispensary operations, packaging and labeling, testing standards, transport manifests, inventory tracking, and civil penalties. It also creates confidentiality protections for patient records, requires child-resistant and non-child-appealing packaging, and limits dispensary sales to qualified cardholders. The bill further amends Indiana’s criminal and traffic laws to provide defenses for authorized medical marijuana users in certain operating-while-intoxicated and marijuana-possession-related cases, while preserving prohibitions on driving or working under the influence.
HB 1178 would add a new Article 53 to the Indiana Code governing medical marijuana and would make conforming changes across criminal, motor vehicle, and controlled-substances statutes. It would carve out lawful conduct for patients, caregivers, and licensed medical marijuana organizations acting in substantial compliance with the program, while preserving criminal penalties for unauthorized possession, distribution, or impaired operation of vehicles and motorboats. The bill would also create new licensing, fee, reporting, inspection, and enforcement authority for the Indiana Department of Health, with fees deposited into the state general fund.
Based on the bill text alone, the legislation appears strongly supportive of medical marijuana access while also emphasizing regulation, public safety, and anti-diversion controls. There are no committee transcripts or recorded votes provided, so there is no direct evidence of legislative debate, support, or opposition in the available context. The structure of the bill suggests an intent to balance patient access with strict oversight and compliance requirements.
The most likely points of contention are the legalization of medical marijuana itself, the scope of protections for patients and caregivers, and the bill’s restrictions on law enforcement cooperation with federal marijuana enforcement. Other potentially disputed provisions include home cultivation, the creation of dispensaries and commercial permits, the confidentiality of patient records, and the employment and discrimination protections for lawful users. The bill also imposes significant regulatory burdens and fees on medical marijuana businesses, which could draw concern from both industry participants and opponents of commercialization.